MS 275

Pricing Availability   Qty
说明: HDAC (Class I) inhibitor
别名: entinostat,SNDX 275
化学名: (Pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate
纯度: ≥99% (HPLC)
说明书
引用文献 (2)
评论 (1)
文献 (4)

生物活性 for MS 275

MS 275 is a class I HDAC inhibitor (IC50 values are 0.18, 0.74, 44.9 and >100 μM for HDAC1, 3, 8 and 6, respectively). Exhibits antiproliferative effects and induces apoptosis in a range of tumor cell lines in vitro and in vivo. Increases estrogen receptor α- and aromatase expression in breast cancer cells. Inhibits PCB-induced neuronal cell death by preventing HDAC3 binding and histone deacetylation within the synapsin-1 promoter.

化合物库 for MS 275

MS 275 is also offered as part of the Tocriscreen Antiviral Library and Tocriscreen Epigenetics Library. 了解 Tocris 化合物库的更多信息。

技术数据 for MS 275

分子量 376.41
公式 C21H20N4O3
储存 Store at -20°C
纯度 ≥99% (HPLC)
CAS Number 209783-80-2
PubChem ID 4261
InChI Key INVTYAOGFAGBOE-UHFFFAOYSA-N
Smiles O=C(C1=CC=C(C=C1)CNC(OCC2=CN=CC=C2)=O)NC3=CC=CC=C3N

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for MS 275

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 37.64 100

制备储备液 for MS 275

以下数据基于产品分子量 376.41。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2.66 mL 13.28 mL 26.57 mL
5 mM 0.53 mL 2.66 mL 5.31 mL
10 mM 0.27 mL 1.33 mL 2.66 mL
50 mM 0.05 mL 0.27 mL 0.53 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for MS 275

参考文献是支持产品生物活性的出版物。

Saito et al (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc.Natl.Acad.Sci. 96 4592 PMID: 10200307

Beckers et al (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int.J.Cancer 121 1138 PMID: 17455259

Formisano et al (2015) MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter. J.Pharmacol.Exp.Ther. 352 236 PMID: 25467131

Sabnis et al (2011) Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letr. Cancer Res. 71 1893 PMID: 21245100


If you know of a relevant reference for MS 275, please let us know.

按产品操作查看相关产品

查看全部 Class I HDAC Inhibitors

关键词: MS 275, MS 275 supplier, MS275, HDAC1, HDAC3, inhibits, inhibitors, class, I, histone, deacetylases, SNDX275, entinostat, SNDX, 275, Class, HDACs, 6208, Tocris Bioscience

2 篇 MS 275 的引用文献

引用文献是使用了 Tocris 产品的出版物。 MS 275 的部分引用包括:

Kim (2018) Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br J Cancer 118 1359 PMID: 29695769

Verónica et al (2020) Differential effects of HDAC inhibitors on PPN oscillatory activity in vivo. Neuropharmacology 165 107922 PMID: 31923766


您是否知道使用了 Tocris MS 275 的优秀论文? 请告知我们.

MS 275 的评论

平均评分: 5 (Based on 1 Review.)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used MS 275?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


TGF beta high responder treated with 1.5 μM MS 275 (HDAC 3 inhibitor) for 48 h. Cell lysates were analysed by western blot..
By Anonymous on 11/15/2019
分析类型: In Vitro
种属: Human
细胞系/组织: C3-TAg tumour cell

TGF beta high responder treated with 1.5 μM MS 275 (HDAC 3 inhibitor) for 48 h. Cell lysates were analysed by western blot.

PMID: 29695769
review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.